Compounds > rubitecan
Page last updated: 2024-08-24

rubitecan and Malignant Melanoma

rubitecan has been researched along with Malignant Melanoma in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
DeJesus, AR; Early, JA; Giovanella, BC; Mendoza, JT; Pantazis, P1
Chatterjee, D; Han, Z; Pantazis, P; Wyche, J1
Bedikian, AY; Ellerhorst, JA; Eton, O; Papadopoulos, NE; Plager, C; Smith, TM1
Densmore, CL; Gautam, A; Gilbert, B; Knight, V; Koshkina, N; Melton, S; Roberts, L; Waldrep, JC1

Trials

1 trial(s) available for rubitecan and Malignant Melanoma

ArticleYear
Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.
    Anti-cancer drugs, 2002, Volume: 13, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; Skin Neoplasms; Treatment Outcome; Uveal Neoplasms

2002

Other Studies

3 other study(ies) available for rubitecan and Malignant Melanoma

ArticleYear
Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro.
    Cancer research, 1994, Feb-01, Volume: 54, Issue:3

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Division; Drug Administration Schedule; Humans; Kinetics; Melanocytes; Melanoma; Mice; Mice, Nude; Tumor Cells, Cultured

1994
Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro.
    Neoplasia (New York, N.Y.), 1999, Volume: 1, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Differentiation; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Flow Cytometry; G2 Phase; Humans; Melanins; Melanoma; Mice; Mice, Nude; Tumor Cells, Cultured

1999
Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
    Gene therapy, 2002, Volume: 9, Issue:5

    Topics: Aerosols; Animals; Antineoplastic Agents; Camptothecin; Combined Modality Therapy; Genes, p53; Genetic Therapy; Liposomes; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Survival Rate

2002